NAS:RTRX (USA) Also trade in: Germany

Retrophin Inc

$ 18.23 -0.78 (-4.1%)
Volume: 397,535 Avg Vol (1m): 400,397
Market Cap $: 755.44 Mil Enterprise Value $: 527.80 Mil
P/E (TTM): 0.00 P/B: 2.66
Earnings Power Value 80.1
Net Current Asset Value 2.26
Tangible Book 3.02
Projected FCF -0.91
Median P/S Value 25.79
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 2.04
Cash-To-Debt ranked lower than
59.60% of 859 companies
in the Drug Manufacturers - Major industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
RTRX: 2.04
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.01, Med: 5.02, Max: 10000
Current: 2.04
0.01
10000
Equity-to-Asset 0.43
Equity-to-Asset ranked lower than
56.85% of 788 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
RTRX: 0.43
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.38, Med: 0.57, Max: 0.63
Current: 0.43
-0.38
0.63
Debt-to-Equity 0.77
Debt-to-Equity ranked lower than
50.34% of 596 companies
in the Drug Manufacturers - Major industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
RTRX: 0.77
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -8.18, Med: 0.15, Max: 77.61
Current: 0.77
-8.18
77.61
Debt-to-EBITDA -2.38
Debt-to-EBITDA ranked higher than
76.57% of 495 companies
in the Drug Manufacturers - Major industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
RTRX: -2.38
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -2.96, Med: -1.25, Max: 0.35
Current: -2.38
-2.96
0.35
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.95
DISTRESS
GREY
SAFE
Beneish M-Score -3.44
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -122.55%
WACC 6.95%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -49.41
Operating Margin ranked lower than
100.00% of 801 companies
in the Drug Manufacturers - Major industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
RTRX: -49.41
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -282.98, Med: -32.29, Max: -19.88
Current: -49.41
-282.98
-19.88
Net Margin % -75.75
Net Margin ranked lower than
81.92% of 802 companies
in the Drug Manufacturers - Major industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
RTRX: -75.75
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -393.36, Med: -38.55, Max: 117.36
Current: -75.75
-393.36
117.36
ROE % -41.47
ROE ranked lower than
76.92% of 832 companies
in the Drug Manufacturers - Major industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
RTRX: -41.47
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -41.47, Med: -17.82, Max: 89.25
Current: -41.47
-41.47
89.25
ROA % -20.30
ROA ranked lower than
74.63% of 871 companies
in the Drug Manufacturers - Major industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
RTRX: -20.3
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -575, Med: -79.48, Max: 36.2
Current: -20.3
-575
36.2
ROC (Joel Greenblatt) % -3500.25
ROC (Joel Greenblatt) ranked lower than
100.00% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
RTRX: -3500.25
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -54335.43, Med: -3196.64, Max: 20603.28
Current: -3500.25
-54335.43
20603.28
3-Year Total Revenue Growth Rate 18.00
3-Year Revenue Growth Rate ranked lower than
100.00% of 689 companies
in the Drug Manufacturers - Major industry.
Industry Max: 291.9, Med: 5.8, Min: -100
RTRX: 15.2
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 52.5
Current: 15.2
0
52.5

» RTRX's 30-Y Financials

Financials (Next Earnings Date: 2019-07-26)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:RTRX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Major    NAICS : 325411    SIC : 2834
Compare SZSE:000915 SZSE:002412 HKSE:01349 XKRX:003090 SHSE:600285 JSE:AIP ASX:MYX SHSE:600713 SHSE:600594 SZSE:300158 BOM:506820 SZSE:002198 SHSE:600488 XPAR:VETO TSE:4559 XKRX:000250 SZSE:002393 TSE:4541 SZSE:300006 SHSE:600666
Traded in other countries 17R.Germany
Address 3721 Valley Centre Drive, Suite 200, San Diego, CA, USA, 92130
Retrophin Inc serves in the healthcare sector based in the United States. As a pharmaceutical products manufacturer, it develops drugs to treat serious and rare diseases. Its suite of drug candidates includes Chenodal, to combat gallstones; Cholbam, which is approved for the treatment of bile acid synthesis disorders and Thiola, which addresses kidney stone formation.

Ratios

Current vs industry vs history
PB Ratio 2.66
PB Ratio ranked lower than
63.86% of 819 companies
in the Drug Manufacturers - Major industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
RTRX: 2.66
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.43, Med: 2.91, Max: 333.66
Current: 2.66
1.43
333.66
PS Ratio 4.51
PS Ratio ranked lower than
74.06% of 775 companies
in the Drug Manufacturers - Major industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
RTRX: 4.51
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 4.36, Med: 6.37, Max: 19750
Current: 4.51
4.36
19750
EV-to-EBIT -4.72
EV-to-EBIT ranked lower than
100.00% of 572 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
RTRX: -4.72
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -34.2, Med: -8.3, Max: 10.4
Current: -4.72
-34.2
10.4
EV-to-EBITDA -5.70
EV-to-EBITDA ranked lower than
100.00% of 597 companies
in the Drug Manufacturers - Major industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
RTRX: -5.7
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -46.4, Med: -10.2, Max: 9.3
Current: -5.7
-46.4
9.3
EV-to-Revenue 3.21
EV-to-Revenue ranked lower than
69.31% of 795 companies
in the Drug Manufacturers - Major industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
RTRX: 3.21
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 2.7, Med: 4.8, Max: 17396.7
Current: 3.21
2.7
17396.7
Current Ratio 4.57
Current Ratio ranked lower than
100.00% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
RTRX: 4.57
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.01, Med: 2.17, Max: 5.07
Current: 4.57
0.01
5.07
Quick Ratio 4.52
Quick Ratio ranked lower than
100.00% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
RTRX: 4.52
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.01, Med: 2.17, Max: 4.98
Current: 4.52
0.01
4.98
Days Inventory 397.48
Days Inventory ranked lower than
100.00% of 755 companies
in the Drug Manufacturers - Major industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
RTRX: 397.48
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 214.88, Med: 278.72, Max: 413.95
Current: 397.48
214.88
413.95
Days Sales Outstanding 28.06
Days Sales Outstanding ranked lower than
100.00% of 770 companies
in the Drug Manufacturers - Major industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
RTRX: 28.06
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 28.06, Med: 45.52, Max: 103.02
Current: 28.06
28.06
103.02
Days Payable 564.56
Days Payable ranked lower than
100.00% of 758 companies
in the Drug Manufacturers - Major industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
RTRX: 564.56
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 459.24, Med: 1276.08, Max: 4553.87
Current: 564.56
459.24
4553.87

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -3.50
3-Year Share Buyback Rate ranked lower than
71.80% of 571 companies
in the Drug Manufacturers - Major industry.
Industry Max: 100, Med: -5.3, Min: -815
RTRX: -3.5
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -592.1, Med: -27.2, Max: -3.5
Current: -3.5
-592.1
-3.5

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 6.04
Price-to-Tangible-Book ranked lower than
87.05% of 749 companies
in the Drug Manufacturers - Major industry.
Industry Max: 972.22, Med: 3.33, Min: 0.05
RTRX: 6.04
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 3.16, Med: 6.84, Max: 11.05
Current: 6.04
3.16
11.05
Price-to-Median-PS-Value 0.71
Price-to-Median-PS-Value ranked lower than
50.61% of 743 companies
in the Drug Manufacturers - Major industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
RTRX: 0.71
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.71, Med: 1.04, Max: 2120
Current: 0.71
0.71
2120
Earnings Yield (Joel Greenblatt) % -21.17
Earnings Yield (Greenblatt) ranked lower than
100.00% of 867 companies
in the Drug Manufacturers - Major industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
RTRX: -21.17
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -21.17, Med: -8.5, Max: 39.1
Current: -21.17
-21.17
39.1

More Statistics

Revenue (TTM) (Mil) $ 165.38
EPS (TTM) $ -3.07
Beta 0.74
Volatility % 31.1
52-Week Range $ 17.53 - 33
Shares Outstanding (Mil) 41.44

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y